1. Home
  2. JAGX vs CDT Comparison

JAGX vs CDT Comparison

Compare JAGX & CDT Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo Jaguar Health Inc.

JAGX

Jaguar Health Inc.

HOLD

Current Price

$2.81

Market Cap

2.2M

Sector

Health Care

ML Signal

HOLD

Logo Conduit Pharmaceuticals Inc.

CDT

Conduit Pharmaceuticals Inc.

HOLD

Current Price

$0.49

Market Cap

2.4M

Sector

Health Care

ML Signal

HOLD

Company Overview

Basic Information
Metric
JAGX
CDT
Founded
2013
2019
Country
United States
United States
Employees
N/A
4
Industry
Biotechnology: Pharmaceutical Preparations
Biotechnology: Pharmaceutical Preparations
Sector
Health Care
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
2.2M
2.4M
IPO Year
2014
N/A

Fundamental Metrics

Financial Performance
Metric
JAGX
CDT
Price
$2.81
$0.49
Analyst Decision
Strong Buy
Analyst Count
1
0
Target Price
$60.00
N/A
AVG Volume (30 Days)
62.4K
12.2M
Earning Date
04-07-2026
04-15-2026
Dividend Yield
N/A
N/A
EPS Growth
82.42
N/A
EPS
N/A
N/A
Revenue
$11,511,000.00
N/A
Revenue This Year
$61.58
N/A
Revenue Next Year
N/A
N/A
P/E Ratio
N/A
N/A
Revenue Growth
N/A
N/A
52 Week Low
$0.22
$0.37
52 Week High
$8.00
$11.00

Technical Indicators

Market Signals
Indicator
JAGX
CDT
Relative Strength Index (RSI) 50.55 35.84
Support Level $1.76 N/A
Resistance Level $4.13 $0.73
Average True Range (ATR) 0.27 0.23
MACD 0.03 0.01
Stochastic Oscillator 72.63 1.87

Price Performance

Historical Comparison
JAGX
CDT

About JAGX Jaguar Health Inc.

Jaguar Health Inc is a commercial-stage pharmaceutical company developing novel proprietary prescription medicines sustainably derived from plants from rainforest areas for gastrointestinal disease states in humans and animals. The Company focuses on conditions associated with overactive bowel, including chronic debilitating diarrhea, urgency, and bowel incontinence. It operates through two segments: animal health, which develops and commercializes products for animals, and human health, with the human health segment generating the maximum revenue and focusing on products such as Mytesi, focusing on human products, specifically Mytesi, approved for symptomatic relief of non-infectious diarrhea in adults with HIV/AIDS on antiretroviral therapy.

About CDT Conduit Pharmaceuticals Inc.

CDT Equity Inc is a data-driven biopharmaceutical development company focused on identifying, enhancing, and advancing high-potential therapeutic assets through scientific innovation and strategic partnerships. It has evolved into a broader, more agile platform that leverages artificial intelligence, solid-form chemistry, and efficient asset repositioning to accelerate the development of novel treatments. The company's pipeline includes candidates that target autoimmune disorders, as well as idiopathic male infertility, oncology, dermatology, rare disease and animal health. It has one operating segment focused on the research and development of clinical assets.

Share on Social Networks: